MRNA vs IBRX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MRNA Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Momentum & Technical while IBRX counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus IBRX at 60.2x Forward P/E and -150.2% operating margin (+52.3% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against IBRX sits in BREAKDOWN (14th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MRNA Revenue | IBRX Revenue | MRNA Op. Margin | IBRX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $140M | $0M | -306.0% | -209338.3% | MRNA |
| FY2019 | $60M | $0M | -906.8% | -7095.9% | MRNA |
| FY2020 | $800M | $0M | -95.0% | -36509.1% | MRNA |
| FY2021 | $18.5B | $0M | 72.0% | -35361.9% | MRNA |
| FY2022 | $19.3B | $0M | 48.9% | -146374.2% | MRNA |
| FY2023 | $6.85B | $0M | -61.9% | -58239.5% | MRNA |
| FY2024 | $3.24B | $10M | -121.9% | -2334.2% | MRNA |
| FY2025 | $1.94B | $110M | -158.1% | -226.0% | MRNA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MRNA | IBRX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $80.7B | $7.0B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | 23.0x | 60.2x | Lower Multiple | MRNA |
| Forward P/E Ratio Valuation | 23.0x | 60.2x | Lower Multiple | MRNA |
| Revenue Growth (YoY) Growth | +29.2% | +52.3% | Higher Growth | IBRX |
| Operating Margin (TTM) Profitability | -80.8% | -150.2% | Higher Margin | MRNA |
| Net Profit Margin Profitability | -110.5% | 0.0% | Higher Margin | IBRX |
| Return on Equity (ROE) Capital Efficiency | -34.5% | 0.0% | Higher ROE | IBRX |
| 52-Week Range Position Momentum | 67% ($22โ$281) | 39% ($2โ$12) | Stronger Trend | MRNA |
| Beta / 30D Volatility Risk Regime | 2.23ฮฒ ยท 78% Vol | 1.68ฮฒ ยท 107% Vol | Lower Realized Risk | MRNA |
| Unified Institutional Score Composite Signal | 40.3 / 100 (SELL) | 61.4 / 100 (BUY) | Higher Composite | IBRX |